Daily Endocrinology Research Analysis
Analyzed 86 papers and selected 3 impactful papers.
Summary
Three high-impact endocrinology studies stand out today: a genotype-first analysis in UK Biobank reveals that monogenic lipodystrophy is more prevalent than recognized and carries substantial cardiometabolic and mortality risks; a real-world head-to-head comparison shows metabolic/bariatric surgery yields greater lifetime ASCVD risk reduction than GLP-1 receptor agonists; and a nationwide target-trial emulation links SGLT2 inhibitors to primary prevention of CKD and cardiovascular events in type 2 diabetes.
Research Themes
- Genotype-first precision endocrinology and hidden monogenic disease burden
- Comparative effectiveness in obesity care and cardiovascular risk reduction
- Early kidney protection and cardiometabolic prevention in type 2 diabetes
Selected Articles
1. Genotype-first approach reveals monogenic lipodystrophy is underdiagnosed, with health and mortality risks.
Using whole-genome sequencing of 490,414 UK Biobank participants, the authors identified 31 carriers of pathogenic variants in 23 lipodystrophy genes (prevalence ~1/15,820), most commonly in PPARG and LMNA. Carriers had similar BMI but lower body fat percentage and exhibited increased cardiometabolic and mortality risks, underscoring substantial underdiagnosis of monogenic lipodystrophy in the general population.
Impact: This genotype-first population study quantifies the hidden burden and risks of monogenic lipodystrophy, shifting screening paradigms toward genetics-informed identification and earlier intervention.
Clinical Implications: Consider genetic evaluation for atypical metabolic phenotypes (e.g., low body fat with insulin resistance/dyslipidemia) and implement proactive cardiometabolic risk management; timely recognition may enable disease-modifying therapies (e.g., metreleptin) and family screening.
Key Findings
- Prevalence of pathogenic monogenic lipodystrophy variants estimated at ~1 in 15,820 in UK Biobank.
- Carriers had similar BMI but significantly lower total body fat percentage versus non-carriers.
- Carriers showed increased cardiometabolic and all-cause mortality risks; PPARG and LMNA variants were most frequent.
Methodological Strengths
- Genotype-first design using whole-genome sequencing in a very large population cohort (n=490,414).
- Comparative analyses against non-carriers and a clinically ascertained cohort to contextualize findings.
Limitations
- Small number of carriers (n=31) limits precision for subgroup analyses.
- Potential healthy volunteer bias in UK Biobank and observational design preclude causal inference.
Future Directions: Prospective, genetics-informed screening in metabolic clinics; standardized variant curation; interventional trials (e.g., metreleptin/PPAR modulators) targeting genetically confirmed cases.
BACKGROUND: Monogenic lipodystrophy is a metabolic disorder that predisposes to diabetes and cardiovascular disease, yet its true prevalence and clinical spectrum remain uncertain. We used a genotype-first approach with an aim to estimate the prevalence, phenotypic spectrum, risk of cardiometabolic disorders and all-cause mortality associated with monogenic lipodystrophy in the population. We also assessed how these clinically unselected cases differ from clinically identified cases. METHODS: We analysed whole-genome sequencing data from 490,414 UK Biobank participants to identify pathogenic variants in 23 lipodystrophy genes. Individuals carrying a pathogenic genotype were compared with non-carriers for anthropometric traits, metabolic biomarkers, cardiometabolic outcomes, and all-cause mortality. We also compared UK Biobank cases with a clinically identified cohort of 58 individuals with monogenic lipodystrophy. FINDINGS: We identified 31 carriers of pathogenic monogenic lipodystrophy variants, giving a prevalence of 1 in 15,820 (95% CI: 1 in 23,282-1 in 11,145). Variants in PPARG and LMNA were most frequent, and prevalence did not differ by sex (P = 0.37). Compared with non-carriers, carriers had similar BMI but lower total body fat percentage (24.7% vs. 31.4%, P = 1.25 × 10
2. Metabolic and Bariatric Surgery vs Glucagon-like peptide-1 Receptor Agonist Therapy: A Head-to-Head Comparison in Improvement of Cardiometabolic Risk Profiles.
In a real-world cohort (n=812), both MBS and GLP-1RA therapy improved estimated cardiovascular risk, but MBS yielded a significantly larger reduction in lifetime ASCVD risk (-8.6% vs -1.7%) along with greater weight loss and lipid improvements. Adjusted analyses confirmed the independent association of MBS with superior lifetime risk reduction.
Impact: Provides head-to-head comparative effectiveness data informing shared decision-making between surgery and GLP-1RA therapy for long-term cardiovascular risk reduction in obesity.
Clinical Implications: For patients eligible for both options, MBS may confer larger lifetime ASCVD risk reductions than GLP-1RA therapy, while GLP-1RA remains valuable for patients who decline or are ineligible for surgery. Counseling should integrate center-specific outcomes, comorbidity profiles, preferences, and access.
Key Findings
- At 1 year, lifetime ASCVD risk decreased more with MBS than with GLP-1RA therapy (-8.6% vs -1.7%; P<.001).
- MBS achieved greater total body weight loss (-27.8% vs -11.1%) and more favorable LDL-C and HDL-C changes.
- Adjusted models showed MBS independently predicted larger lifetime risk reduction (β -6.92; 95% CI -9.22 to -4.62).
Methodological Strengths
- Head-to-head comparison in a large real-world cohort with multivariable adjustment.
- Clinically meaningful primary outcomes (10-year and lifetime ASCVD risk) with supporting lipid and weight endpoints.
Limitations
- Retrospective, nonrandomized design with baseline risk differences between groups.
- Single health system and 12-month follow-up limit generalizability and long-term inference.
Future Directions: Prospective randomized or pragmatic trials comparing surgical and pharmacologic strategies, long-term (>5–10 years) cardiovascular outcomes, and cost-effectiveness across diverse populations.
OBJECTIVE: To compare 1-year changes in estimated 10-year and lifetime atherosclerotic cardiovascular disease (ASCVD) risk following metabolic and bariatric surgery (MBS) versus glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy among adults with obesity. SUMMARY BACKGROUND DATA: Obesity is a major driver of ASCVD through adverse metabolic and inflammatory pathways. Metabolic and bariatric surgery and GLP-1 receptor agonists represent the most effective contemporary treatments for obesity and are increasingly used to mitigate cardiovascular risk. However, their comparative effects on integrated short-term and lifetime ASCVD risk in real-world clinical practice remain incompletely characterized. METHODS: We conducted a retrospective cohort study of adults with obesity (body mass index ≥30 kg/m²) who underwent MBS or initiated GLP-1RA therapy between 2020 and 2023 within a large tertiary health care system in the United States. Participants were identified from electronic health records and followed for 12 months. Primary outcomes were 1-year changes in estimated 10-year and lifetime ASCVD risk. Secondary outcomes included percent total body weight loss, blood pressure, and lipid parameters. Multivariable linear regression models were used to adjust for baseline body mass index and baseline ASCVD risk. RESULTS: The final cohort included 812 patients, of whom 579 underwent MBS and 233 initiated GLP-1RA therapy. At baseline, patients receiving GLP-1RAs were older and had higher estimated ASCVD risk. At 1 year, reductions in 10-year ASCVD risk were similar between groups (-0.8% vs. -1.1%; P=.36). In contrast, lifetime ASCVD risk decreased significantly more following MBS than GLP-1RA therapy (-8.6% vs. -1.7%; P<.001). MBS was associated with greater percent total body weight loss (-27.8% vs. -11.1%; P<.001) and more favorable lipid changes, including larger reductions in low-density lipoprotein cholesterol and greater increases in high-density lipoprotein cholesterol. After adjustment, MBS remained independently associated with a greater reduction in lifetime ASCVD risk compared with GLP-1RA therapy (β -6.92; 95% CI -9.22 to -4.62). CONCLUSIONS: In this real-world cohort, both MBS and GLP-1RA therapy were associated with improvements in estimated cardiovascular risk, but MBS conferred substantially greater reductions in lifetime ASCVD risk, accompanied by superior weight loss and lipid improvements. These findings highlight the complementary roles of surgical and pharmacologic therapies in obesity management and may inform strategies to optimize long-term cardiovascular risk reduction.
3. SGLT2 inhibitors and the risk of incident chronic kidney disease in type 2 diabetes: a nationwide emulated target trial in Taiwan.
In an emulated target trial using Taiwan’s nationwide database with 11,617 matched pairs, SGLT2 inhibitor use was associated with lower risks of incident CKD, macroalbuminuria, AKI, MACE, heart failure hospitalization, myocardial infarction, and all-cause mortality among T2D patients without baseline CKD.
Impact: Extends SGLT2 inhibitor benefits to primary prevention of CKD and cardiovascular events in T2D without preexisting CKD, supporting earlier initiation in clinical practice.
Clinical Implications: SGLT2 inhibitors should be considered early in T2D to prevent kidney disease and major cardiovascular events, even before CKD onset; monitoring remains essential to address rare adverse events.
Key Findings
- SGLT2 inhibitor use lowered incident CKD risk (aHR 0.86) and macroalbuminuria (aHR 0.85) versus non-use.
- Reduced AKI (aHR 0.71) and trends toward lower dialysis initiation (aHR 0.46; 95% CI 0.20–1.06).
- Cardiovascular and mortality benefits: lower MACE (aHR 0.84), HF hospitalization (0.85), MI (0.68), and all-cause mortality (0.73).
Methodological Strengths
- Nationwide emulated target-trial design with 1:1 propensity score matching (11,617 pairs).
- Robust Cox modeling with multiple clinically relevant renal and cardiovascular endpoints.
Limitations
- Residual confounding and misclassification are possible in claims-based observational data.
- Follow-up duration and generalizability outside Taiwan are not fully defined.
Future Directions: Prospective trials for CKD primary prevention with SGLT2i, subgroup analyses (e.g., age, HbA1c, BP, albuminuria strata), and health-economic evaluations.
OBJECTIVE: To compare the risk of incident chronic kidney disease (CKD), cardiovascular events, and mortality between users of sodium-glucose cotransporter 2 (SGLT2) inhibitors and non-users in patients with type 2 diabetes (T2D) without preexisting CKD. METHODS: By Taiwan's National Health Insurance Research Database (2016-2021), 1:1 propensity score matching, 11,617 pairs of SGLT2 inhibitor users and non-users with T2D and no baseline CKD were analyzed. Cox models estimated adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) for clinical outcomes. RESULTS: SGLT2 inhibitor use was associated with lower risks of incident CKD (aHR 0.86, 95% CI 0.83-0.89), macroalbuminuria (aHR 0.85, 95% CI 0.82-0.89), acute kidney injury (aHR 0.71, 95% CI 0.59-0.86), and dialysis (aHR 0.46, 95% CI 0.20-1.06). Cardiovascular benefits included reduced risks of major adverse cardiovascular events (aHR 0.84, 95% CI 0.76-0.92), hospitalization for heart failure (aHR 0.85, 95% CI 0.76-0.96), and myocardial infarction (aHR 0.68, 95% CI 0.52-0.89). All-cause mortality was also lower among SGLT2 inhibitor users (aHR 0.73, 95% CI 0.64-0.82). CONCLUSIONS: In patients with T2D without preexisting CKD, SGLT2 inhibitor use was associated with reduced risks of kidney disease, cardiovascular events, and mortality.